Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TARA logo TARA
Upturn stock ratingUpturn stock rating
TARA logo

Protara Therapeutics Inc (TARA)

Upturn stock ratingUpturn stock rating
$2.88
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: TARA (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

7 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $22.17

Year Target Price $22.17

Analyst’s Price TargetsFor last 52 week
$22.17Target price
Low$1.59
Current$2.88
high$6.88

Analysis of Past Performance

Type Stock
Historic Profit 201.1%
Avg. Invested days 53
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 111.12M USD
Price to earnings Ratio -
1Y Target Price 22.17
Price to earnings Ratio -
1Y Target Price 22.17
Volume (30-day avg) -
Beta 1.36
52 Weeks Range 1.59 - 6.88
Updated Date 06/29/2025
52 Weeks Range 1.59 - 6.88
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.49

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -27.16%
Return on Equity (TTM) -41.88%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -9406054
Price to Sales(TTM) -
Enterprise Value -9406054
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.74
Shares Outstanding 38581900
Shares Floating 34182373
Shares Outstanding 38581900
Shares Floating 34182373
Percent Insiders 3.61
Percent Institutions 76.24

Analyst Ratings

Rating 4.71
Target Price 22.17
Buy 2
Strong Buy 5
Buy 2
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Protara Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Protara Therapeutics Inc. is a clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases. Founded with the goal of addressing unmet medical needs, the company has focused on developing its pipeline through strategic acquisitions and internal development programs.

business area logo Core Business Areas

  • TARA-002: An investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC).

leadership logo Leadership and Structure

The company is led by a management team with experience in oncology and rare diseases. The organizational structure is typical for a biotech company, with departments focusing on R&D, clinical development, and commercial strategy.

Top Products and Market Share

overview logo Key Offerings

  • TARA-002: Investigational cell therapy for NMIBC. It is currently in clinical trials. Market share data is not yet available as the product is not yet approved. Key competitors in the NMIBC space include Ferring Pharmaceuticals, Merck and Urogen Pharma.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and dynamic, with companies focused on developing novel therapies for various diseases. The oncology segment is particularly active.

Positioning

Protara is positioned as a clinical-stage company focused on developing therapies for cancer and rare diseases. Its competitive advantage lies in its investigational cell therapy TARA-002.

Total Addressable Market (TAM)

The TAM for NMIBC is significant and growing. Protara is positioned to capture a portion of this market if TARA-002 is approved. Market size is estimated to be over $1 Billion USD.

Upturn SWOT Analysis

Strengths

  • Promising clinical-stage asset (TARA-002)
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Dependence on a single lead asset
  • Limited financial resources compared to larger pharmaceutical companies
  • Clinical trial risks and regulatory hurdles

Opportunities

  • Successful clinical trial results leading to regulatory approval
  • Expansion of pipeline through acquisitions or partnerships
  • Potential for Orphan Drug designation and accelerated approval pathways

Threats

  • Clinical trial failures
  • Competition from other companies developing therapies for NMIBC
  • Regulatory setbacks
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • FGEN
  • UROG

Competitive Landscape

Protara's success depends on demonstrating the efficacy and safety of TARA-002 compared to existing and emerging therapies for NMIBC.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by the advancement of TARA-002 through clinical trials.

Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of TARA-002. Analyst estimates will depend on clinical data.

Recent Initiatives: Recent initiatives include ongoing clinical trials for TARA-002 and exploration of potential partnerships.

Summary

Protara Therapeutics is a clinical-stage biotech company with potential in TARA-002 for NMIBC. Its success hinges on positive clinical trial outcomes and regulatory approval. Funding and competition are significant risks, while successful development presents considerable opportunity. Given the clinical stage, the company is speculative.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Protara Therapeutics Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2014-10-22
Co-founder, CEO, President & Director Mr. Jesse Shefferman
Sector Healthcare
Industry Biotechnology
Full time employees 28
Full time employees 28

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.